Proactive Investors - Run By Investors For Investors

Lancor Scientific to have its screening device approved for six cancers by March

Lancor Scientific's Roland Schlesinger updates Proactive London's Andrew Scott on latest developments with their cancer screening device.

He says they've already got one cancer device approved with five more soon to follow.

''We're in the process of moving towards mass production capabilities which should be complete by the end of January ... and then we'll be ready for sales''.

''The pre-sales of everything based on our current regulatory status can start around the end of October or November''.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here  
Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full LANCO profile View Profile

Lancor Scientific Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use